SecBot SecBot
8-K ·Filed May 7, 2026

CRL

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago SEC0001100682-26-000036
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

CRL's core business continues to shrink organically (-1.5%) with accelerating margin compression. The CDMO divestiture removes a drag but also reduces revenue scale. Watch for Q2 DSA bookings data as a leading indicator of demand recovery, management expects return to organic growth in H2 2026. The $800M buyback authorization provides a floor but does not offset declining fundamentals.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$180.78
T+0 close · May 7, 2026 · via day close
Latest settled
+28.61%
T+60 · $232.51
Vs SPY
+26.50%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $180.78entry
  2. T+1 · 6mo ago −1.88%α −2.71% · $177.39
  3. T+5 · 6mo ago −9.92%α −11.42% · $162.85
  4. T+20 · 6mo ago −0.51%α −3.64% · $179.87
  5. T+60 · 4mo ago +28.61%α +26.50% · $232.51

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CRL reported Q1 2026 non-GAAP EPS of $2.06, a 12.0% YoY decline from $2.34, and revenue of $995.8M (+1.2% reported, -1.5% organic). The company reaffirmed its 2026 organic revenue and non-GAAP EPS guidance but lowered reported revenue guidance by ~50bps on FX. Non-GAAP operating margin contracted to 16.3% from 19.1% due to higher direct costs and unfavorable mix. The CDMO/Cell Solutions divestiture closed on May 6, and the company repurchased $200M in stock during the quarter.

Key Financial Metrics

EPS
$2.06
est $1.96 · +5.1%
Revenue
$995.8M
est $977.4M · +1.9% · +1.2% YoY
Rating
miss
Guidance
-1.5% to -0.5% organic growth
maintained

Key Facts

  • Q1 2026 revenue $995.8M, +1.2% reported, -1.5% organic YoY
  • Non-GAAP EPS $2.06, -12.0% YoY from $2.34
  • Non-GAAP operating margin 16.3%, down from 19.1% YoY
  • GAAP net loss $(14.8)M or $(0.30)/share, vs net income $25.5M a year ago
  • Reaffirmed 2026 organic revenue guidance (-1.5% to -0.5%) and non-GAAP EPS ($10.80-$11.30)
  • Lowered 2026 reported revenue guidance by ~50bps to (5.5%)-(4.0%) on FX
  • Completed CDMO and Cell Solutions divestiture to GI Partners on May 6
  • Repurchased 1.1M shares for $200M in Q1; $800M remaining on authorization
  • DSA segment organic revenue -1.4%, RMS -5.5%, Manufacturing +2.9%
  • Operating cash flow $41.1M, down from $171.7M in Q1 2025

Financial Impact

Non-GAAP EPS declined 12% YoY; operating margin compressed 280bps; organic revenue declined for third consecutive quarter

revenueepsoperating margincash flow

Risk Factors

  • Organic revenue decline persisting into H2 2026, delaying expected inflection
  • Further margin compression from unfavorable RMS mix and DSA study costs
  • Higher leverage post-divestiture (debt increased $527M QoQ to $2.66B)
  • FX headwinds reducing reported revenue and EPS

Market Snapshot

Exchange
NYSE
Sector
Services-Commercial Physical & Biological Research
Analyst Consensus
63% bullish (24 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001100682-26-000036
Document: crl-20260507.htm0001100682-26-000036
Document: 0001100682-26-000036-index-headers.html0001100682-26-000036
Document: 0001100682-26-000036-index.html0001100682-26-000036
Document: 0001100682-26-000036.txt0001100682-26-000036
8-K Data (Synthetic)0001100682-26-000036

US Market Status

Market Closed · Opens in 8h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026